What if Parkinson's disease had secret boss variants hiding in the same level, and scientists kept looting only the easiest one to pick up?

That, more or less, is the drama in a new 2025 Cell Reports paper on alpha-synuclein, the protein that famously misbehaves in Parkinson's disease and dementia with Lewy bodies [1]. When alpha-synuclein folds the wrong way, it can stack into amyloid fibrils - long, stubborn protein fibers that help make Lewy bodies, the microscopic clumps pathologists see in affected brains. The twist is that these fibrils are not all identical. They can come in different structural "polymorphs," which is science-speak for same ingredients, different cursed origami.

For a while, a lot of the field's structural work focused on fibrils purified out of diseased brain tissue. That gave researchers an important shape called the "Lewy fold" [2,3]. Useful, yes. Complete, maybe not. Purification is a little like fishing with a weirdly selective net. You catch what survives the process well, not necessarily everything that was swimming around causing trouble in the first place.

Same Villain, Different Skin

The new study tried a workaround. Instead of purifying alpha-synuclein fibrils out of brain tissue first, the researchers used in situ amplification. In plain English: they took brain homogenates from people with Parkinson's disease or dementia with Lewy bodies, then encouraged any existing alpha-synuclein "seeds" in that messy biological soup to grow enough for cryo-EM imaging [1]. Think of it as turning up the microphone on rare protein troublemakers without making them leave the room first.

That mattered. The team found that each case contained a mix of fibril shapes, not one neat uniform structure. Some looked similar to the already known Lewy fold. But one especially interesting structure, called ISA-P1, looked different from the classic Lewy fold and more similar to folds previously linked to multiple system atrophy and juvenile-onset synucleinopathy [1].

That is a big deal because it suggests Parkinson's disease and dementia with Lewy bodies may harbor more structural variety than we thought. Not every alpha-synuclein aggregate is wearing the same outfit. Some may share family resemblance with aggregates from other synuclein diseases. The protein world, unfortunately, loves a multiverse.

Why This Matters Outside Cryo-EM Nerd Camp

If different fibril shapes behave differently, the consequences could spill into diagnosis, prognosis, and treatment design. This is already a live issue in the biomarker world. Over the last few years, seed amplification assays have become one of the hottest tools in Parkinson's research because they can detect tiny amounts of misfolded alpha-synuclein in cerebrospinal fluid and other samples with impressive sensitivity [4-7]. Very cool. Very useful. Also not magic.

Recent reviews and commentaries make the same point from different angles: a positive seed amplification assay tells you pathological alpha-synuclein is probably present, but it does not automatically explain which subtype of disease a person has, how fast it will progress, or which exact fibril architecture is doing the damage [4,6,7]. In other words, the test can tell you the monster is in the basement. It cannot yet tell you whether it is a raccoon, a dragon, or three raccoons in a trench coat.

This new paper sharpens that problem. If standard purification methods or standard amplification setups favor some fibril polymorphs over others, then scientists could end up with a slightly biased picture of what is actually in the brain [1,2]. That matters for drug discovery. A therapy designed to bind one alpha-synuclein structure might whiff on another. Same for imaging tracers. Same for lab models. Biology loves nothing more than making one "general solution" look silly in public.

The Real Plot Twist

The most intriguing part here is not just "we found a weird fibril." It is that Parkinson's disease and dementia with Lewy bodies may contain ensembles of alpha-synuclein structures rather than one canonical bad actor [1]. That fits with a broader trend in the field: researchers increasingly see synucleinopathies as structurally and biologically heterogeneous, with different strains or conformations targeting different cells, regions, and clinical trajectories [3-5].

If that view holds up, future diagnostics may need to do more than answer yes-or-no. They may need to identify which alpha-synuclein fold is present, in what mix, and whether that mix changes over time. That is harder, obviously. The brain is not a clean RPG inventory screen where every item comes labeled and color-coded. It is more like opening a junk drawer that somehow contains paper clips, batteries, an Allen wrench, and one emotionally threatening rubber band.

Still, this study gives the field something valuable: a warning label. Be careful what your preparation method selects for. The protein clumps you can purify most easily may not be the whole story. And in diseases as devastating as Parkinson's and Lewy body dementia, "not the whole story" is exactly where expensive mistakes like to hide.

References

1. Cao T, Zhao Q, Yao Y, et al. In situ amplification of alpha-synuclein amyloid fibril reveals a distinct polymorph related to Parkinson's disease and dementia with Lewy body. Cell Reports. 2025;44(11):116564. DOI: https://doi.org/10.1016/j.celrep.2025.116564. PubMed: https://pubmed.ncbi.nlm.nih.gov/41240336/

2. Dhavale DD, Barclay AM, Borcik CG, et al. Structure of alpha-synuclein fibrils derived from human Lewy body dementia tissue. Nature Communications. 2024;15:2750. DOI: https://doi.org/10.1038/s41467-024-46832-5. PubMed: https://pubmed.ncbi.nlm.nih.gov/38553463/

3. Leak RK, Clark RN, Abbas M, et al. Current insights and assumptions on alpha-synuclein in Lewy body disease. Acta Neuropathologica. 2024;148(1):18. DOI: https://doi.org/10.1007/s00401-024-02781-3. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC11324801/

4. Soto C. Alpha-synuclein seed amplification technology for Parkinson's disease and related synucleinopathies. Trends in Biotechnology. 2024;42(7):829-841. DOI: https://doi.org/10.1016/j.tibtech.2024.01.007.

5. Bellomo G, Russo MJ, Concha-Marambio L, et al. Alpha-synuclein seed amplification assays for diagnosing synucleinopathies: the way forward. Neurology. 2022;99(6):241-250. DOI: https://doi.org/10.1212/WNL.0000000000200878. PubMed: https://pubmed.ncbi.nlm.nih.gov/35914941/

6. Espay AJ, Morgante F, Merola A, et al. The alpha-synuclein seed amplification assay: interpreting a test of Parkinson's pathology. Parkinsonism & Related Disorders. 2025;132:107256. DOI: https://doi.org/10.1016/j.parkreldis.2024.107256. PubMed: https://pubmed.ncbi.nlm.nih.gov/39794217/

7. Morris HR, Lees AJ. Limitations of the alpha-synuclein seed amplification assay in clinical practice: understanding the pathological diversity of Parkinson syndrome. JAMA Neurology. 2024;81(9):905-906. DOI: https://doi.org/10.1001/jamaneurol.2024.2381.

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.